Product Description
Emalex Biosciences is developing Ecopipam as a treatment for Tourette’s and other central nervous system disorders. (Sourced from: https://emalexbiosciences.com/research-development/#drug-pipeline)
Mechanisms of Action: D1 Antagonist,D5 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Emalex Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Other|Rett Syndrome|Tourette Syndrome
Phase 2: Childhood-Onset Fluency Disorder|Stuttering
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EBS-101-TD-391 | P3 |
Unknown Status |
Other |
2027-04-13 |
|
| EBS-101-HV-107 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-12-22 |
|
| D1AMOND | P3 |
Active, not recruiting |
Rett Syndrome|Tourette Syndrome |
2024-12-01 |
|
| EBS-101-TD-391 | P3 |
Recruiting |
Tourette Syndrome|Rett Syndrome |
2024-11-01 |